Falorni

What Falorni does

Falorni S.r.l. is an Italian pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 1954 in Florence, operating as a privately held group with two divisions: Falorni Pharma and Falorni Nutra. Falorni Pharma provides contract secondary packaging (50+ million packages/year on double shifts), serialization and aggregation across EU, USA, Russia, KSA, and China markets via four customized lines (partnered with Antares Vision), manual visual inspection (1.5 million vials/year), batch reconditioning, batch record release with on-site Qualified Persons, packaging material procurement, and integrated GDP-compliant logistics including cold chain (2-8°C) and controlled substances storage. The company serves pharmaceutical manufacturers producing standard and specialty products including sterile injectables, ophthalmics, narcotics, blood derivatives, and orphan drugs.

Falorni Nutra, established in 2019, extends the pharmaceutical DNA into probiotic and food supplement CDMO services, operating a 5,000+ sqm GMP facility with dedicated HVAC systems controlling humidity down to 20% Rh, double air-lock contamination prevention, and scale-up capabilities through 10L, 100L, and 500L mixers. The Nutra division offers full-service product development from idea screening through formulation, prototype, clinical study management, and commercial manufacturing of bulk powders, hard capsules, blister packs, and stick packs.

Revenue is generated through customized quote-based B2B contracts with pharmaceutical and nutraceutical companies, sold through direct enterprise field sales with dedicated project managers and long-term co-investment partnership models. The go-to-market is relationship-driven, targeting primarily Italian and European pharmaceutical enterprises; a logo list includes 21+ named clients including Menarini, Recordati, Alfasigma, Dompè, Lilly, Aurobindo, Fidia, Molteni, Farmigea, and Urgo. Regulatory authorizations span GMP (human and food supplements), ISO 13485 medical devices, and Italian Ministerial Decrees for veterinary medicinal products and controlled substances, providing a meaningful regulatory moat. The company is owned by a private group that acquired it from Procter & Gamble in 2001; no venture capital or institutional investor involvement is disclosed.

Name

Falorni

Legal name

Falorni S.r.l.

Website

https://falornipharma.com

Company type

Private

Founded year

1954

Operating status

Operating

Headcount range

11–50 employees

Short description

Falorni is an Italian pharmaceutical CDMO (founded 1954) operating Falorni Pharma for contract packaging, serialization, and visual inspection, and Falorni Nutra for probiotic and food supplement manufacturing, serving enterprise pharma and nutraceutical clients globally.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing and Packaging

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Pharmaceutical contract packaging
• Pharmaceutical CDMO services
• Serialization and aggregation
• Probiotic manufacturing
• Nutraceutical product development

Headquarters

HQ city

Sesto Fiorentino

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Packaging Services: Secondary packaging of pharmaceutical products including liquids, solids, sterile injectables, ophthalmic products, and medicated patches. Services include serialization, aggregation, labeling, and batch reconditioning. Revenue generated through service contracts with pharmaceutical companies.
2. CDMO Manufacturing Services: Contract development and manufacturing of finished probiotic and food supplement products. Includes bulk powder mixing, hard capsules, blister packaging, bottle packaging, and stick packs. Full service from R&D through production release.
3. Logistics and Supply Chain Services: Integrated logistics including warehousing, temperature-controlled storage, cold chain management, and distribution. Manages semi-finished and finished products through the pharmaceutical supply chain.
4. R&D and Clinical Study Services: Product development services including idea conceptualization, formulation, clinical study management, and regulatory support. Single point of contact integrating R&D, clinical studies, and final production.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Falorni is a Contract Development and Manufacturing Organization (CDMO) for pharmaceutical and nutraceutical companies, organized into Falorni Pharma and Falorni Nutra. It provides contract secondary packaging, serialization and aggregation compliant with EU/USA/Russia/KSA/China regulations, manual visual inspection, batch release, reconditioning, and GDP-compliant cold chain logistics. It also provides full-service probiotic and food supplement development from idea and formulation through prototype, clinical study, scale-up, and GMP manufacturing in a 5,000+ sqm facility with dedicated HVAC and contamination control.

Product overview

Falorni is a Contract Development and Manufacturing Organization (CDMO) operating since 1954, organized into two divisions: Falorni Pharma for pharmaceutical contract packaging and Falorni Nutra for probiotic and food supplement manufacturing. Falorni Pharma offers secondary packaging (50+ million packages/year capacity), serialization and aggregation (4 lines, EU/USA/Russia/KSA/China markets), visual inspection (1.5 million pieces/year), logistics, packaging material procurement, batch record release, and batch reconditioning services. Falorni Nutra provides full-service product development from idea through manufacturing, including formulation, prototype and scale-up (10-500L mixers), clinical studies, and GMP manufacturing for probiotics and food supplements (5,000 sqm facility with dedicated HVAC for humidity control to 20% Rh). The company integrates R&D, clinical studies, and production with a centralized monitoring system and holds GMP, ISO 13485, and Italian ministerial authorizations.

Differentiator

Problem solved

Functional benefit

Products and services

• Secondary Packaging Contract secondary packaging services for pharmaceutical products including liquids, solids, semi-solids, sterile injectables, ophthalmic products, and medicated patches on automated and semi-automatic lines. Yearly capacity exceeds 50 million packages on double shifts.
• Serialization and Aggregation End-to-end and track-and-trace serialization and aggregation services across 4 customized lines plus a dedicated big and custom box serialization line, ensuring FMD anti-counterfeiting compliance for pharmaceutical clients.
• Visual Inspection Manual visual inspection for standard and special vials, PET vials with overwrap, pre-filled syringes, and lyophilisates, with annual volumes of approximately 1.5 million pieces.
• Logistics Full GDP-compliant logistics management for semi-finished and finished pharmaceutical products including warehousing, temperature-sensitive and cold chain handling, and distribution with temperature monitoring devices.
• Packaging Material Procurement Purchase, management, and quality control of pharmaceutical packaging materials including labels, boxes, and inserts, supported by print proof software that scans texts and characteristics of printed materials.
• Batch Record Release Batch release documentation services with on-site Qualified Persons (QP) who can release batches to the market and ensure compliance with safety, quality, and regulatory standards.
• Batch Reconditioning Dynamic batch reconditioning services for pharmaceutical products including blister labeling, replacement of package inserts and cartons, un-labeling and re-labeling of bottles, and application of labels on already printed data.
• Falorni Pharma (Sub-brand) Pharmaceutical CDMO sub-brand providing secondary packaging, serialization, visual inspection, logistics, batch release, and reconditioning since 1954.
• Idea to Product Development Full-service product development from idea to market-ready formulation, including therapeutic area assessment, molecule screening, and preliminary solution screening conducted by the R&D team.
• Formulation Product formulation services ensuring standards of stability, homogeneity, and effectiveness, with R&D team proposing new and technologically advanced solutions for industrialization.
• Price and Market Orientation Business development services for market segment selection and strategy, including formulation adjustments to determine the best product for a given market context.
• Prototype and Scale-up Formulation development with 10L, 100L, and 500L mixers to evaluate scale-up characteristics from early development through industrial production.
• Clinical Study Clinical trial development services covering regulatory, strategic, logistical, and monitoring phases, leveraging over a decade of partnerships with clinical study providers.
• GMP Manufacturing for Probiotics and Food Supplements GMP manufacturing for probiotics and food supplements including bulk powder mixing, hard capsules (sizes 00, 0, 1, 3), blister packs, bottles, and stick packs in a 5,000+ sqm facility with HVAC humidity control down to 20% Rh.
• Falorni Nutra (Sub-brand) Nutraceutical CDMO sub-brand specializing in high-level probiotics and food supplements with GMP manufacturing capabilities for live and viable probiotic products.

Quantifiable outcome

• Over 50 million packages produced annually
• +3 more outcomes

Named customers16 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Antares VisioncoreTechnology or IntegrationStrategic partnership with Antares Vision, a global leader in integrated serialization systems. This partnership enables Falorni to offer services compliant with the latest FMD (Falsified Medicines Directive) anti-counterfeiting legislation. Antares Vision provides the serialization technology infrastructure that supports Falorni's track-and-trace capabilities across multiple international markets.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Alcami Corporation: US-based pharmaceutical CDMO offering contract manufacturing, analytical, and packaging services across sterile and solid dosage forms — comparable mid-sized CDMO service mix.
• ACG Group: Global supplier of pharmaceutical processing and packaging machinery and integrated services — comparable in packaging-line solutions and serialization, though more equipment-focused than service-focused.
• AptarGroup (Aptar Pharma): Pharmaceutical packaging solutions provider with drug-delivery, elastomeric, and serialization/aggregation services — directly comparable to Falorni's secondary packaging and serialization offering.
• Bormioli Pharma: Italian pharmaceutical packaging specialist offering primary containers, closures, and packaging services — directly comparable Italian-headquartered pharma packaging peer to Falorni.
• Hovione: European pharmaceutical CDMO specializing in API development, particle engineering, and contract manufacturing with GMP facilities — comparable pharma CDMO service model and European base.
• Corden Pharma: European pharmaceutical CDMO offering API manufacturing, finished dosage forms, and packaging services — comparable CDMO service portfolio with strong European pharma customer base.
• Recipharm: European-headquartered pharmaceutical CDMO offering contract manufacturing and secondary packaging for solid, semi-solid, and sterile dosage forms — directly comparable business model and service mix to Falorni Pharma.

Regional players

• Procemsa: Italian pharmaceutical contract manufacturer offering secondary packaging and small-batch production — comparable Italian-headquartered CDMO with overlapping packaging focus.

Broad incumbents

• Catalent: Global pharmaceutical CDMO incumbent offering contract packaging, serialization, and clinical/commercial supply across multiple dosage forms — much larger scale but overlapping pharma CDMO services.
• Eurofins CDMO: Global life-sciences testing and CDMO platform (including Cambrex acquisition) offering pharmaceutical development, manufacturing, and packaging services — broader scope but overlapping pharma CDMO functions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/falorni-srl

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Falorni